The European Organisation for Research and Treatment of Cancer (EORTC) is a pan-European, non-profit, independent research organisation that develops, conducts, co-ordinates and stimulates high-quality translational and clinical research aimed at improving the standards of treatment for cancer patients in Europe. 1 to €2,500 for an initial ethics committee application and from €0 to €1,000 when submitting a substantial trial amendment. A number of Member States agreed to a waiver for non-commercial sponsors through the 'legal recognition' of academic research. 12 Likewise, fees paid to Competent Authorities range from €0 to €4,000 for an initial application and from €0 to €1,500 for a substantial amendment with waivers for non-commercial sponsors. 13 Some Ethics Committees, as in the case of Germany, also charge for the review of suspected unexpected serious adverse reactions (SUSARs). European regulatory authorities have adopted a very broad interpretation of the IMP concept, resulting in enormous additional costs to the sponsor. In Austria and Hungary, for example, every medication specified in the protocol must be supplied free of charge, whether a standard or experimental medication, control arm or supportive treatment. 14 In Denmark, non-IMPs are also provided for free. 15 In Germany, an IMP is any product used to initiate specific reactions in human beings. 16 The single 'sponsorship' model of the Directive poses another hurdle. Others suggest using tailored approaches to data monitoring according to the level of risk a trial presents. 18 The existing safety reporting system under the EU CTD is unnecessarily complex in terms of definitions and reporting requirements, resulting from the way in which the rules were transposed into national law. Further complicating this is the fact that This symposium, hosted by the EORTC, NCI and AACR, will bring together academics and scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology.
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Understanding the pathways and mechanisms which cause cancer and regulate the biological behaviour of tumor cells has lead to the development of numerous new agents and innovative targets for clinical trials. This conference has been organised to refl ect the many recent advances in the early development of promising new compounds, which are at different stages of preclinical and clinical development. It will bring together delegates from all over the world igniting an enormous exchange of information, as well as promoting and developing global partnerships in translational research.
The conference has been developed to ensure the maximum amount of interaction and discussion. We hope that the plenary sessions and the workshops will be informative and lively with extensive discussions. Further information is available on the EORTC website: www.eortc.be/ENA2008.htm Vist us at www.eortc.be costs and increasing demands on resources are encountered daily. The EORTC Headquarters budget has increased six-fold over recent years (see Figure 4) and the staff has tripled despite a drop in the number of newly activated clinical trials and number of treated patients (see Partnerships between industry and non-commercial academic research organisations can only lead to a win-win situation. 19 These measures will ensure early access to innovative agents and novel therapeutic modalities, increase the competitiveness of European research and, most importantly, provide patients with the best available therapy.
In spite of the challenges presented by the EU CTD, the EORTC is actively seeking concrete solutions to remain at the forefront of cancer research while working to improve the Directive. A current EORTC priority is research that will identify individual cancer gene signatures that clinicians will use one day to 'tailor' patient treatment using 'targeted' therapies. Another priority is the study of rare types of cancers in small 'niche' patient populations. Both initiatives demand scientific expertise but also significantly large patient numbers, which in turn requires a pan-European, multinational, harmonised approach to co-ordinate and conduct such trials. If Europe is to remain competitive and expand its capacity for medical research excellence, innovative solutions, novel research approaches, successful industry-academia partnerships and, above all, a new EU CTD are clearly needed. I 
